Analyst Price Target is $11.75
▲ +94.86% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for BELLUS Health in the last 3 months. The average price target is $11.75, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 94.86% upside from the last price of $6.03.
Current Consensus is
The current consensus among 6 investment analysts is to buy stock in BELLUS Health. This Buy consensus rating has held steady for over two years.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.